Trial to Evaluate the Efficacy and Safety of Substrate Ablation of Monomorphic Ventricular Tachycardia

• Status: Completed
• Trial end date: 2017-09-30
• Target enrollment: 0
• Participant gender: All

Summary

To compare the efficacy and safety of substrate-based radiofrequency catheter ablation vs. antiarrhythmic drug therapy in patients with ischemic cardiomyopathy and scar-related sustained monomorphic ventricular tachycardia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital General Universitario Gregorio Marañon
• Treatments: Amiodarone; Anti-Arrhythmia Agents; Sotalol

Criteria

Inclusion Criteria:

• Ischemic cardiomyopathy, with ischemic myocardial scar

• Sustained monomorphic ventricular tachycardia

• Age > 18 years

• Prior ICD implantation

Exclusion Criteria:

• VT storm

• NYHA functional class IV

• Additional indication for antiarrhythmic drug therapy

• Contraindication for both study drugs (amiodarone and sotalol).

• Uncontrolled myocardial ischemia.

• LV thrombus.

• Non-ischemic VT substrate.

• Contraindications for anticoagulation.

• Prior substrate ablation in the previous 6 months

• Cr > 2.5 mg/dL

• Mitral AND aortic mechanical valvular prosthesis